BioNTech (BNTX) stock slides as 2026 revenue outlook misses forecasts and a CEO succession begins. Read more here ...

Nothing about the recent past, present, or foreseeable future seems all that compelling.

BioNTech stock crumbled Tuesday after the cofounders of the German biotech announced their plan to step down.

If you are wondering whether BioNTech is starting to look like value after the Covid vaccine boom faded, or if the current price still feels rich, this article walks through what the numbers actually ...

BioNTech (BNTX) reported upbeat Q4 results and FY26 sales guidance below estimates. Shares gained 7.7% on Wednesday. Analysts have mixed opinions.

The company’s co-founders said they are leaving to start a new mRNA-based company.

In BioNTech’s search for a new CEO—following the announcement earlier Tuesday that Uğu | Leerink Partners called the departure of BioNTech CEO Uğur Şahin and his wife, and CMO Özlem Türeci, to ...

Investors in BioNTech faced a one-two punch of negative developments, sending the company's stock tumbling approximately 19% to a fresh 52-week low. The double blow consisted of a disappointing ...

The stock was down 14% premarket after BioNTech announced the departures and issued revenue guidance that fell short of Wall Street’s forecasts.

An unhealthy combination of factors resulted in an unhealthy day on the stock market for next-generation healthcare company BioNTech (NASDAQ: BNTX). Investors were concerned about the latest top-level ...

BioNTech’s CEO and his fellow co-founder will depart the biopharma by the end of the year to head up a new company focused on “next generation mRNA innovations.” Uğur Şahin, M.D., who is currently the ...

Ugur Sahin and Özlem Türeci were instrumental in developing the first COVID-19 vaccine to be approved in the West. Now they ...